Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk

Annals of Oncology

Volumn 25, Issue 5, 2014, Pages 1059-1064

  Lestuzzi, C ^a   Vaccher, E ^b   Talamini, R ^c   Lleshi, A ^b   Meneguzzo, N ^a   Viel, E ^a   Scalone, S ^b   Tartuferi, L ^a   Buonadonna, A ^b   Ejiofor, L ^b   Schmoll, H J ^d  

^a Cardiology Unit

^b Department of Oncology ^*

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

5 fluorouracil; 5 FU; 5 FU effort ischemia; cardiotoxicity; chemotherapy cardiotoxicity; fluorouracil toxicity

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; FLUOROURACIL;

ADULT; AGED; CHEMICALLY INDUCED; EXERCISE; EXERCISE TEST; FEMALE; HUMAN; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; RISK; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; EXERCISE TEST; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PHYSICAL EXERTION; RISK; YOUNG ADULT;

EID: 84908214707     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu055     Document Type: Article

References (28)

1. Becker, K., Erckenbrecht, J.F., Häussinger, D., et al. Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs 57 (1999), 475–484 Review doi:10.2165/00003495-199957040-00003.
2. Saif, M.W., Shah, M.M., Shah, A.R., Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf 8 (2009), 191–202 doi:10.1517/14740330902733961.
3. Keefe, D.L., Roistacher, N., Pierri, M.K., Clinical cardiotoxicity of 5-fluorouracil. J Clin Pharmacol 33 (1993), 1060–1070 doi:10.1002/j.1552-4604.1993.tb01943.x.
4. Schöber, C., Papageorgiou, E., Harstrick, A., et al. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer 72 (1993), 2242–2247 doi:10.1002/1097-0142(19931001)72:7<2242::AID-CNCR2820720730>3.0.CO;2-E.
5. Khan, M.A., Masood, N., Husain, N., Ahmad, B., Aziz, T., Naeem, A., A retrospective study of cardiotoxicities induced by 5-fluouracil (5-FU) and 5-FU based chemotherapy regimens in Pakistani adult cancer patients at Shaukat Khanum Memorial Cancer Hospital & Research Center. J Pak Med Assoc 62 (2012), 430–434 doi:10.1159/000227226.
6. de Forni, M., Malet-Martino, M.C., Jaillais, P., et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 10 (1992), 1795–1801.
7. Akhtar, S.S., Salim, K.S., Bano, Z.A., Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study. Oncology 50 (1993), 441–444 doi:10.1159/000227226.
8. Tsibiribi, P., Descotes, J., Lombard-Bohas, C., et al. Cardiotoxicity of 5-fluorouracil in 1350 patients with no prior history of heart disease. Bull Cancer 93:3 (2006), E27–E30.
9. Tsavaris, N., Kosmas, C., Vadiaka, M., et al. Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy—a survey of 427 patients. Med Sci Monit 8 (2002), PI51–PI57.
10. Kosmas, C., Kallistratos, M.S., Kopterides, P., et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 134 (2008), 75–82 doi:10.1007/s00432-007-0250-9.
11. Meydan, N., Kundak, I., Yavuzsen, T., et al. Cardiotoxicity of de Gramont's regimen: incidence, clinical characteristics and long-term follow-up. Jpn J Clin Oncol 35 (2005), 265–270 doi:10.1093/jjco/hyi071.
12. Rezkalla, S., Kloner, R.A., Ensley, J., et al. Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. J Clin Oncol 7 (1989), 509–514.
13. Robben, N.C., Pippas, A.W., Moore, J.O., The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy. Cancer 71 (1993), 493–509 Review doi:10.1002/1097-0142(19930115)71:2<493::AID-CNCR2820710235>3.0.CO;2-C.
14. Weidmann, B., Jansen, W., Heider, A., et al. 5-Fluorouracil cardiotoxicity with left ventricular dysfunction under different dosing regimens. Am J Cardiol 75 (1995), 194–195 doi:10.1016/S0002-9149(00)80079-X.
15. Lestuzzi, C., Tartuferi, L., Corona, G., Capecitabine (and 5 fluorouracil) cardiotoxicity. Metabolic considerations. Breast J 17 (2011), 564–565 doi:10.1111/j.1524-4741.2011.01120.x.
16. Lestuzzi, C., Viel, E., Picano, E., et al. Coronary vasospasm as a cause of effort-related myocardial ischemia during low-dose chronic continuous infusion of 5-fluorouracil. Am J Med 111:4 (2001), 316–318 doi:10.1016/S0002-9343(01)00808-7.
17. Lestuzzi, C., Crivellari, D., Rigo, F., et al. Capecitabine cardiac toxicity presenting as effort angina: a case report. J Cardiovasc Med (Hagerstown) 11 (2010), 700–703 doi:10.2459/JCM.0b013e328332e873.
18. Coughlin, S., Das, S., Lee, J., et al. Capecitabine induced vasospastic angina. Int J Cardiol 130 (2008), e34–e36 doi:10.1016/j.ijcard.2007.06.152.
19. Jensen, S.A., Hasbak, P., Mortensen, J., et al. Fluorouracil induces myocardial ischemia with increase of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle. J Clin Oncol 28 (2010), 5280–5286 doi:10.1200/JCO.2009.27.3953.
20. Lemaire, L., Malet-Martino, M.C., de Forni, M., et al. Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug. Br J Cancer 66 (1992), 119–127 doi:10.1038/bjc.1992.227.
21. The 5th Joint Task Force of the ESC and other Societies, European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J 33 (2012), 1635–1701 doi:10.1093/eurheartj/ehs092.
22. Labianca, R., Beretta, G., Clerici, M., et al. Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori 68 (1982), 505–510.
23. Weiner, D.A., Ryan, T.J., McCabe, C.H., et al. Risk of developing an acute myocardial infarction or sudden coronary death in patients with exercise-induced silent myocardial ischemia. A report from the Coronary Artery Surgery Study (CASS) registry. Am J Cardiol 62 (1988), 1155–1158 doi:10.1016/0002-9149(88)90251-2.
24. Ng, M., Cunningham, D., Norman, A.R., The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur J Cancer 41 (2005), 1542–1546 doi:10.1016/j.ejca.2005.03.027.
25. Jensen, S.A., Sørensen, J.B., Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 58 (2006), 487–493 doi:10.1007/s00280-005-0178-1.
26. Gradishar, W., Vokes, E., Schilsky, R., et al. Vascular events in patients receiving high-dose infusional 5-fluorouracil-based chemotherapy: the University of Chicago experience. Med Pediatr Oncol 19 (1991), 8–15 doi:10.1002/mpo.2950190103.
27. Ambrosy, A.P., Kunz, P.L., Fisher, G.A., et al. Capecitabine-induced chest pain relieved by diltiazem. Am J Cardiol 110 (2012), 1623–1626 doi:10.1016/j.amjcard.2012.07.026.
28. Deboever, G., Hiltrop, N., Cool, M., et al. Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity. Clin Colorectal Cancer 12:1 (2013), 8–14 doi:10.1016/j.clcc.2012.09.003.